460 related articles for article (PubMed ID: 26366937)
1. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
2. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
Chasen MR; Rapoport BL
Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
[TBL] [Abstract][Full Text] [Related]
3. Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting.
Navari R
Drugs Today (Barc); 2016 Aug; 52(8):431-438. PubMed ID: 27722211
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
Rojas C; Slusher BS
Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
[TBL] [Abstract][Full Text] [Related]
5. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
Navari RM
Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
[No Abstract] [Full Text] [Related]
6. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
Rapoport BL; Aapro M; Chasen MR; Jordan K; Navari RM; Schnadig I; Schwartzberg L
Drug Des Devel Ther; 2017; 11():2621-2629. PubMed ID: 28919712
[TBL] [Abstract][Full Text] [Related]
7. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy.
Rapoport B; van Eeden R; Smit T
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):17-29. PubMed ID: 27894202
[TBL] [Abstract][Full Text] [Related]
8. Rolapitant: first global approval.
Syed YY
Drugs; 2015 Nov; 75(16):1941-5. PubMed ID: 26467681
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting.
Ahmed H; Hammad AM; Abushouk AI; Zidan M; Salem M; Negida A; Abdel-Daim MM
Curr Probl Cancer; 2018; 42(2):241-255. PubMed ID: 29310827
[TBL] [Abstract][Full Text] [Related]
10. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK
BoĆĄnjak SM; Gralla RJ; Schwartzberg L
Support Care Cancer; 2017 May; 25(5):1661-1671. PubMed ID: 28108820
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy.
Rapoport B; Smit T
Expert Opin Drug Saf; 2017 Jun; 16(6):697-710. PubMed ID: 28460548
[TBL] [Abstract][Full Text] [Related]
12. Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.
Rapoport BL
Rev Recent Clin Trials; 2017; 12(3):193-201. PubMed ID: 28393710
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
15. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
[TBL] [Abstract][Full Text] [Related]
16. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
Navari RM
Paediatr Drugs; 2017 Jun; 19(3):213-222. PubMed ID: 28447301
[TBL] [Abstract][Full Text] [Related]
17. Rolapitant (Varubi) for prevention and delayed chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther; 2016 Feb; 58(1487):17-8. PubMed ID: 26812124
[No Abstract] [Full Text] [Related]
18. State of the Art Antiemetic Therapy for Cancer Patients.
Lau TK; Yip CH; Yeo W
Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
[TBL] [Abstract][Full Text] [Related]
19. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
Zhang Z; Zhang Y; Chen G; Hong S; Yang Y; Fang W; Luo F; Chen X; Ma Y; Zhao Y; Zhan J; Xue C; Hou X; Zhou T; Ma S; Gao F; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
Oncologist; 2018 May; 23(5):603-616. PubMed ID: 29330211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]